EP4114359A1 — Pharmaceutical compositions of a kinase inhibitor
Assigned to Aurigene Oncology Ltd · Expires 2023-01-11 · 3y expired
What this patent protects
The present invention relates to pharmaceutical compositions comprising hydrochloride salt of N-(2',4'-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1'-biphenyl]-3-yl)cyclopropanesulfonamide (I) as an active ingredient and copovidone as an excipient. Compo…
USPTO Abstract
The present invention relates to pharmaceutical compositions comprising hydrochloride salt of N-(2',4'-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1'-biphenyl]-3-yl)cyclopropanesulfonamide (I) as an active ingredient and copovidone as an excipient. Compound (I) is a selective inhibitor ofFGFR/VEGFR kinase families and is useful in the treatment of cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.